# Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Canonical URL: https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-a-business-update
Ticker: ELVN
Company: Enliven Therapeutics
Source: Enliven Therapeutics
Published: 2026-05-07 20:05 EST
Original Source URL: https://ir.enliventherapeutics.com
## Summary

Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first

## Article Body
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first
## Recent Company News
- 2026-06-03 20:05 EST — [Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-host-webcast-conference-call-to-discuss-phase-1-elvn-001-clinical-data-being-presented-at-eha-2026-congress) — Source: Enliven Therapeutics
- 2026-05-21 20:05 EST — [Enliven Therapeutics to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-present-at-upcoming-investor-conferences) — Source: Enliven Therapeutics
- 2026-05-12 13:53 EST — [Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-oral-presentation-at-the-eha-2026-congress-featuring-additional-positive-phase-1-clinical-trial-data-for-elvn-001-in-cml) — Source: Enliven Therapeutics
- 2026-05-07 20:05 EST — [Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-a-business-update) — Source: Enliven Therapeutics
- 2026-03-03 21:05 EST — [Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update) — Source: Enliven Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)